Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 8/20 | 0.53 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.52 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.52 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.48 |
| ▸ | CFTR | P13569 | 1/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.45 |
| ▸ | FABP4 | P15090 | 2/20 | 0.44 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.44 |
| ▸ | THRA | P10827 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | FNTA | P49354 | 1/20 | 0.42 |
| ▸ | FNTB | P49356 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.42 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4200412 | 0.85 | PTGDR2 (0.69) | PTGDR2PLA2G2ATHRATHRB | |
| SCHEMBL9584600 | 0.80 | PTGDR2 (0.50) | PTGDR2AKR1B10AKR1B1FOLH1FABP4 | |
| SCHEMBL13802264 | 0.74 | PTGDR2 (0.60) | PTGDR2FOLH1PLA2G2ATHRATHRB | |
| SCHEMBL8175838 | 0.74 | PTGER4 (0.47) | PTGDR2FOLH1THRATHRBPPARG | |
| SCHEMBL27749337 | 0.73 | PTGES (0.59) | PTGDR2ABCB1PLA2G2APPARG | |
| SCHEMBL4210031 | 0.73 | THRA (0.60) | PTGDR2FOLH1PLA2G2ATHRATHRB | |
| SCHEMBL9584151 | 0.73 | FOLH1 (0.46) | PTGDR2FOLH1PLA2G2ATHRATHRB | |
| SCHEMBL3853784 | 0.73 | PLA2G2A (0.53) | PTGDR2PLA2G2ATHRATHRBPPARG | |
| SCHEMBL3853782 | 0.73 | PLA2G2A (0.53) | PTGDR2PLA2G2ATHRATHRBPPARG | |
| SCHEMBL8174537 | 0.72 | PTGDR2 (0.52) | PTGDR2ABCB1FOLH1PLA2G2ATHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | APP, PSEN2, PSEN1 | PTGDR2 2287/4885AKR1B10 890/4885AKR1B1 914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.